CCKBR and neoplasm: Aim: DOTA-MGS5 is a novel minigastrin (MG) analogue with improved tumour-to-kidney ratio and optimised in vivo stability which can be considered a promising new candidate for the theranostic use in neoplasms that express the cholecystokinin-2 receptor (CCK2R).